IMNM · Immunome, Inc.
$22.01
+4.50% last session
End-of-day data · updated 2026-07-25
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-10.5
Dividend yield
—
Beta
2.07
Avg volume
1M
Employees
0K
2D change
0.91%
5D change
0.23%
10D change
-3.10%
30D change
14.48%
60D change
1.37%
MTD change
3.35%
YTD change
3.40%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMNM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Barclays
Overweight$36.00
+63.6% vs priceGoldman Sachs
Buy$26.00
+18.1% vs priceJP Morgan
Overweight$22.00
-0.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | Wedbush | Reiterates | Outperform | $31.00 |
| 2026-06-12 | Wedbush | Reiterates | Outperform | $31.00 |
| 2026-05-28 | Truist Securities | Maintains | Buy | $36.00 → $37.00 |
| 2026-05-28 | Barclays | Initiates | Overweight | $0.00 → $36.00 |
| 2026-05-15 | Leerink Partners | Maintains | Outperform | $37.00 → $33.00 |
| 2026-05-13 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-03-04 | Craig-Hallum | Maintains | Buy | $33.00 → $36.00 |
| 2026-03-04 | Stephens & Co. | Maintains | Overweight | $33.00 → $30.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.2% above the 50-day MA ($21.06).
- Price vs 200-day MA: Trading 10.9% above the 200-day MA ($20.74).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.99) and high ($26.97).
IMNM Price Chart
Loading chart for IMNM…
Fundamentals
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.